Wolf Theiss advises Bain Capital in a $4.53 bn divestment of Lonza

The multi-level transaction closed earlier this month and the cross-border team, led by Jacek Michalski (Partner, Warsaw) for Poland and Tereza Naucova (Counsel, Prague) for the Czech Republic, ran complex due diligence, drafted transaction documentation, assessed relevant FDI issues, assisted in the related corporate matters and provided post-closing legal support. This cross-border transaction involved jurisdictions of Poland and the Czech Republic (served by Wolf Theiss), as well as UK, Switzerland, Germany, Spain, the Netherlands, India, Japan and China.

The Wolf Theiss team further consisted of Joanna Wajdzik (Senior Associate) and Anna Nowodworska (Associate) from Warsaw office, and Katerina Kulhankova (Senior Associate) and Barbora Malimankova (Senior Associate) from Prague office. Wolf Theiss supported a team from Kirkland & Ellis International LLP on this case.

Lonza is a leading development and manufacturing partner for pharmaceutical and biotech companies worldwide. Lonza Specialty Ingredients operates at 17 production sites worldwide and employs approximately 2,800 people. The business is a leading supplier of microbial control solutions for professional hygiene and personal care products. It also offers the custom development and manufacturing of specialty chemicals and composites to support the electronics, aerospace, food and agrochemical industries.

Bain Capital Private Equity, LP operates as a private equity firm. The company, which has made more than 1,000 primary and add-on investments since its founding in 1984 in Boston, invests in consumer, retail, dining, healthcare, technology, financial services, media, telecommunication, and business sectors.